## Amendments to the Claims

**1-18. (Cancelled)**

**19. (Currently amended)** An aqueous liquid preparation comprising at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.

**20. (Previously presented)** The aqueous liquid preparation according to claim 19, wherein the alkyl aryl polyether alcohol type polymer is tyloxapol;

wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.5 w/v %; and

wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is selected from a range of about 0.01 to about 0.5 w/v %.

**21. (Previously presented)** The aqueous liquid preparation according to claim 20, wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.

**22. (Previously presented)** The aqueous liquid preparation according to claim 21, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is selected from a range of about 0.05 to about 0.2 w/v %.

**23. (Previously presented)** The aqueous liquid preparation according to claim 22, wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.3 w/v %.

**24. (Previously presented)** The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

**25. (Previously presented)** The aqueous liquid preparation according to claim 24, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**26. (Previously presented)** The aqueous liquid preparation according to claim 25, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**27. (Previously presented)** The aqueous liquid preparation according to claim 26, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**28. (Previously presented)** The aqueous liquid preparation according to claim 27, wherein the pH is from about 7 to about 9.

**29. (Previously presented)** The aqueous liquid preparation according to claim 28, wherein the pH is from about 7.5 to about 8.5.

**30. (Cancelled)**

**31. (Previously presented)** The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

**32. (Previously presented)** The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.3 w/v %.

**33. (Previously presented)** The aqueous liquid preparation according to claim 32, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**34. (Previously presented)** The aqueous liquid preparation according to claim 33, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**35. (Cancelled)**

**36. (Previously presented)** The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**37. (Previously presented)** The aqueous liquid preparation according to claim 36, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**38. (Previously presented)** The aqueous liquid preparation according to claim 37, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**39. (Withdrawn-currently amended)** A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate

thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, to obtain an aqueous liquid preparation comprising at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising tyloxapol or polyethylene glycol monostearate, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.

**40. (Withdrawn-currently amended)** A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative, to obtain an aqueous liquid preparation comprising at least the following two components, the first component comprising 2-amino-3-(4- bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising tyloxapol or polyethylene glycol monostearate, together with a preservative, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.

**41. (Currently amended)** An aqueous liquid preparation consisting essentially of at least the following two components, wherein the first component comprising is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising is an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.

**42. (Previously presented)** The aqueous liquid preparation according to claim 41, wherein the alkyl aryl polyether alcohol type polymer is tyloxapol;

wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.5 w/v %; and

wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is selected from a range of about 0.01 to about 0.5 w/v %.

**43. (Previously presented)** The aqueous liquid preparation according to claim 42, wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.

**44. (Previously presented)** The aqueous liquid preparation according to claim 43, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is selected from a range of about 0.05 to about 0.2 w/v %.

**45. (Previously presented)** The aqueous liquid preparation according to claim 44, wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.3 w/v %.

**46. (Previously presented)** The aqueous liquid preparation according to claim 45, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

**47. (Previously presented)** The aqueous liquid preparation according to claim 46, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**48. (Previously presented)** The aqueous liquid preparation according to claim 47, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**49. (Previously presented)** The aqueous liquid preparation according to claim 48, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**50. (Previously presented)** The aqueous liquid preparation according to claim 49, wherein the pH is from about 7 to about 9.

**51. (Previously presented)** The aqueous liquid preparation according to claim 50, wherein the pH is from about 7.5 to about 8.5.

**52. (Cancelled)**

**53. (Previously presented)** The aqueous liquid preparation according to claim 45, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

**54. (Previously presented)** The aqueous liquid preparation according to claim 53, wherein the concentration of the tyloxapol is about 0.3 w/v %.

**55. (Previously presented)** The aqueous liquid preparation according to claim 54, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**56. (Previously presented)** The aqueous liquid preparation according to claim 55, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**57. (Cancelled)**

**58. (Previously presented)** The aqueous liquid preparation according to claim 53, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**59. (Previously presented)** The aqueous liquid preparation according to claim 58, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**60. (Previously presented)** The aqueous liquid preparation according to claim 59, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**61. (Withdrawn-currently amended)** A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, to obtain an aqueous liquid preparation consisting essentially of at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising tyloxapol or polyethylene glycol monostearate, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.

**62. (Currently amended)** A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation

containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative, to obtain an aqueous liquid preparation consisting essentially of at least the following two components, the first component comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising tyloxapol or polyethylene glycol monostearate, together with a preservative, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.

**63. (Currently amended)** An aqueous liquid preparation consisting of the following two components, the first component comprising is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component comprising is an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester, and water, and optionally at least one preservative, isotonic, buffer, thickener, stabilizer, chelating agent, pH controlling agent, or perfume, wherein said liquid preparation is formulated for ophthalmic administration~~in the form of an eye drop~~.